Oncology · Adrenocortical Carcinoma

Managing Mitotane and Your Hormones

At a Glance

Mitotane for adrenocortical carcinoma can sharply reduce the body's cortisol production. Safe treatment requires prescribed steroid replacement, regular blood and thyroid monitoring, attention to neurological symptoms, and an emergency injection plan.

Mitotane (brand name Lysodren) is a powerful medication used to treat Adrenocortical Carcinoma. It works in two ways: by slowing the growth of cancer cells and by being adrenolytic—meaning it heavily suppresses and damages adrenal tissue ^[1]^[2]. While it is a cornerstone of treatment, it has a narrow “therapeutic window,” meaning the dose must be carefully managed to be effective without becoming toxic ^[3].

The “Sweet Spot”: Target Levels and Toxicity

To ensure mitotane is working, your doctor will regularly measure the amount of the drug in your blood. A commonly cited target range is 14 to 20 mg/L ^[3]^[4].

Below 14 mg/L: May be less effective in preventing recurrence, though some effectiveness can still occur ^[5].
Above 20 mg/L: This significantly increases the risk of severe neurotoxicity ^[4]. However, serious neurological symptoms—including confusion, extreme sleepiness, tremors, and problems with balance and coordination—can occur even without levels above 20 mg/L ^[6]^[7]. Contact your treatment team promptly for any marked neurological changes.

Critical Tip for Blood Tests: To get an accurate reading, your blood should be drawn as a trough level—at least 12 hours after your last dose ^[8]. You should also check with your lab regarding fasting rules, as high levels of fats (triglycerides) in your blood can sometimes cause the lab to report a “spuriously high” mitotane level ^[8]^[9].

Managing Mandatory Adrenal Insufficiency

Because mitotane suppresses adrenal tissue, you can expect that your body will struggle to produce its own cortisol (the “stress hormone”). This is called adrenal insufficiency ^[1]. You must take glucocorticoid replacement (usually hydrocortisone or cortisone acetate) ^[10].

Mitotane activates an enzyme in your liver (CYP3A4) that “chews up” medications like hydrocortisone much faster than normal ^[11]^[12]. As a result, patients on mitotane require much higher doses of steroids to stay safe ^[11]^[10]. Never start, stop, or change your replacement doses without your endocrinology team’s plan.

Emergency Preparedness: Your Safety Net

A sudden illness, injury, or severe stress can lead to a life-threatening adrenal crisis ^[13]. You must have an emergency plan in place:

Stress Dosing: Obtain an individualized sick-day plan from your doctor outlining exactly how to increase your oral steroids if you have a fever, infection, or surgery ^[14]^[13].
The Emergency Kit: You should always carry a hydrocortisone injection kit (generally 100 mg for adults; children need weight-appropriate instructions) ^[13]^[15].
When to Call 911: If you cannot keep tablets down, have severe vomiting or diarrhea, faint, become confused, feel unusually weak, or have very low blood pressure, you must administer the prescribed injection and seek immediate emergency medical assessment (call 911) ^[15]^[16].
Emergency Identification: You must wear a medical-alert bracelet and carry a steroid emergency card ^[13]^[17].

Drug Interactions and Contraception

Mitotane strongly induces drug-metabolizing enzymes (like CYP3A4), which can alter the effectiveness of many other medicines, including making hormonal contraception unreliable. You must discuss pregnancy prevention and perform a complete medication and supplement review with your oncology and endocrine teams.

Monitoring Your Thyroid and Lipids

Mitotane affects other systems in your body that require close monitoring:

Thyroid Function: Mitotane often causes central hypothyroidism ^[18]. Standard tests that check TSH are unreliable while on mitotane; your doctor must check your Free T4 levels instead to see if you need thyroid hormone replacement ^[19]^[20].
Cholesterol and Lipids: Mitotane can significantly raise your LDL (“bad”) cholesterol and triglycerides ^[21]^[19]. Uncontrolled high triglycerides can also interfere with your mitotane blood tests ^[9]^[8].

Common questions in this guide

What mitotane level is usually considered the treatment target?

Doctors often use a blood level of 14 to 20 mg/L as a target range. Levels below 14 mg/L may be less effective for preventing recurrence, while levels above 20 mg/L raise the risk of nervous-system toxicity; symptoms can occur even below that level.

When should my mitotane blood test be taken?

The sample is usually drawn as a trough, meaning at least 12 hours after your last dose. Ask the laboratory whether you should fast, because high triglycerides can make the reported level falsely high.

Why is my hydrocortisone dose higher while I take mitotane?

Mitotane increases a liver enzyme that breaks down hydrocortisone and similar steroid medicines more quickly. You may therefore need a higher replacement dose, but only your endocrinology team should change it.

What should I do if illness keeps me from taking my steroid tablets?

Follow the personalized sick-day plan from your treatment team. If you cannot keep tablets down, have severe vomiting or diarrhea, faint, become confused, feel unusually weak, or have very low blood pressure, use your prescribed emergency hydrocortisone injection and seek immediate emergency care by calling 911.

How is thyroid function checked during mitotane treatment?

Mitotane can cause a form of underactive thyroid in which TSH is less reliable. Your clinician should use the Free T4 blood level to decide whether thyroid hormone replacement is needed.

Can mitotane affect birth control or other medicines?

Yes. Mitotane speeds up the liver's processing of many medicines, so hormonal contraception may not work reliably and other medications or supplements may be affected. Review every medicine and supplement with your oncology and endocrinology teams.

Which neurological changes can mitotane cause?

Confusion, extreme sleepiness, tremors, dizziness, or trouble with balance and coordination can signal mitotane-related nervous-system toxicity. Contact your treatment team promptly for marked or new neurological changes, even if your measured level is not above 20 mg/L.

Get notified when new evidence is published on adrenal carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Mitotane treatment commonly uses a target blood level of 14 to 20 mg/L, measured as a trough at least 12 hours after the last dose, but toxicity symptoms can occur below 20 mg/L.
Mitotane suppresses cortisol production and speeds the breakdown of hydrocortisone, so steroid replacement often requires higher doses under endocrinology guidance.
Patients need an individualized sick-day plan, an emergency hydrocortisone injection, and medical-alert identification because illness can trigger a life-threatening adrenal crisis.
Mitotane can make hormonal contraception unreliable and can interact with other medicines and supplements by increasing drug-metabolizing enzyme activity.
Thyroid monitoring should use Free T4 rather than relying on TSH, and LDL cholesterol and triglycerides should also be monitored.

References (21)

1
Patient Experience of Adrenocortical Carcinoma: Views from a Patient, His Physician and a Patient Association.
Büdenbender M, Heitz-Lamy C, Fassnacht M
Advances in therapy 2026; doi:10.1007/s12325-026-03718-w.
PMID: 42631797
2
Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma.
Poirier J, Gagnon N, Terzolo M, et al.
Cancers 2020; (12(3)) doi:10.3390/cancers12030639.
PMID: 32164326
3
A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring.
Friedl B, Kurlbaum M, Kroiss M, et al.
Analytical and bioanalytical chemistry 2019; (411(17)):3951-3962 doi:10.1007/s00216-019-01868-1.
PMID: 31093700
4
Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up.
Feliu C, Cazaubon Y, Guillemin H, et al.
Biomedical chromatography : BMC 2017; (31(11)) doi:10.1002/bmc.3993.
PMID: 28432798
5
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
Megerle F, Herrmann W, Schloetelburg W, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(4)):1686-1695 doi:10.1210/jc.2017-02591.
PMID: 29452402
6
Role of Mitotane in Adrenocortical Carcinoma - Review and State of the art.
Paragliola RM, Torino F, Papi G, et al.
European endocrinology 2018; (14(2)):62-66 doi:10.17925/EE.2018.14.2.62.
PMID: 30349596
7
Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study.
Mormando M, Galiè E, Bianchini M, et al.
Frontiers in oncology 2023; (13()):1222002 doi:10.3389/fonc.2023.1222002.
PMID: 37645432
8
Hypertriglyceridemia and its impact on mitotane monitoring in adrenocortical carcinoma.
Martens S, Lapauw B
Endocrinology, diabetes & metabolism case reports 2023; (2023(4)).
PMID: 38056082
9
Dyslipidemia causes overestimation of plasma mitotane measurements.
Paci A, Hescot S, Seck A, et al.
Endocrinology, diabetes & metabolism case reports 2016; (2016()):150135 doi:10.1530/EDM-15-0135.
PMID: 27298727
10
Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study.
Tuli G, Munarin J, Vallero SG, et al.
Children (Basel, Switzerland) 2025; (12(8)) doi:10.3390/children12081031.
PMID: 40868483
11
Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.
Weigel M, Hahner S, Sherlock M, et al.
Clinical endocrinology 2017; (86(4)):499-505 doi:10.1111/cen.13302.
PMID: 28063163
12
Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G, Puglisi S, Zaggia B, et al.
European journal of endocrinology 2017; (177(4)):361-367 doi:10.1530/EJE-17-0452.
PMID: 28780517
13
[Emergency card, emergency medication, and information leaflet for the prevention and treatment of adrenal crisis (Addison crisis): an Austrian consensus document].
Pilz S, Krebs M, Bonfig W, et al.
Journal fur klinische Endokrinologie und Stoffwechsel 2022; (15(1)):5-27 doi:10.1007/s41969-022-00155-2.
PMID: 35251520
14
Adrenal insufficiency.
Husebye ES, Pearce SH, Krone NP, Kämpe O
Lancet (London, England) 2021; (397(10274)):613-629 doi:10.1016/S0140-6736(21)00136-7.
PMID: 33484633
15
Diagnosis and management of secondary adrenal crisis.
Martel-Duguech L, Poirier J, Bourdeau I, Lacroix A
Reviews in endocrine & metabolic disorders 2024; (25(3)):619-637 doi:10.1007/s11154-024-09877-x.
PMID: 38411891
16
Treatment and Prevention of Adrenal Crisis and Family Education
Çamtosun E, Sangün Ö
Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):80-92 doi:10.4274/jcrpe.galenos.2024.2024-6-12-S.
PMID: 39713905
17
Guidance for the prevention and emergency management of adult patients with adrenal insufficiency.
Simpson H, Tomlinson J, Wass J, et al.
Clinical medicine (London, England) 2020; (20(4)):371-378 doi:10.7861/clinmed.2019-0324.
PMID: 32675141
18
Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
Poirier J, Godemel S, Mourot A, et al.
The Journal of clinical endocrinology and metabolism 2023; (108(9)):2336-2342 doi:10.1210/clinem/dgad115.
PMID: 36856782
19
Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review.
Bianchini M, Puliani G, Chiefari A, et al.
Cancers 2021; (13(19)) doi:10.3390/cancers13195001.
PMID: 34638485
20
Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.
Vikner ME, Krogh J, Daugaard G, Andreassen M
Clinical endocrinology 2021; (94(2)):141-149 doi:10.1111/cen.14345.
PMID: 32996176
21
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma.
Gagnon N, Bernard S, Paquette M, et al.
Endocrine oncology (Bristol, England) 2022; (2(1)):1-8 doi:10.1530/EO-21-0021.
PMID: 37435450

This page is for informational purposes only and does not constitute medical advice. Mitotane and steroid doses, blood-test timing, and emergency plans must be individualized with your oncology and endocrinology teams.

Guide Contents